231 related articles for article (PubMed ID: 15180564)
1. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases.
Fischer PM
Curr Med Chem; 2004 Jun; 11(12):1563-83. PubMed ID: 15180564
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
3. Chemical genomic and proteomic methods for determining kinase inhibitor selectivity.
Krishnamurty R; Maly DJ
Comb Chem High Throughput Screen; 2007 Sep; 10(8):652-66. PubMed ID: 18045078
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
5. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
6. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets.
Vieth M; Higgs RE; Robertson DH; Shapiro M; Gragg EA; Hemmerle H
Biochim Biophys Acta; 2004 Mar; 1697(1-2):243-57. PubMed ID: 15023365
[TBL] [Abstract][Full Text] [Related]
7. The use of computational methods in the discovery and design of kinase inhibitors.
Woolfrey JR; Weston GS
Curr Pharm Des; 2002; 8(17):1527-45. PubMed ID: 12052199
[TBL] [Abstract][Full Text] [Related]
8. Identification of enzyme inhibitors using combinatorial libraries.
Batra S; Srinivasan T; Rastogi SK; Kundu B
Curr Med Chem; 2002 Feb; 9(3):307-19. PubMed ID: 11860360
[TBL] [Abstract][Full Text] [Related]
9. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
10. Imatinib: a selective tyrosine kinase inhibitor.
Manley PW; Cowan-Jacob SW; Buchdunger E; Fabbro D; Fendrich G; Furet P; Meyer T; Zimmermann J
Eur J Cancer; 2002 Sep; 38 Suppl 5():S19-27. PubMed ID: 12528769
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
12. ATP site-directed competitive and irreversible inhibitors of protein kinases.
García-Echeverría C; Traxler P; Evans DB
Med Res Rev; 2000 Jan; 20(1):28-57. PubMed ID: 10608920
[TBL] [Abstract][Full Text] [Related]
13. Creating chemical diversity to target protein kinases.
Li B; Liu Y; Uno T; Gray N
Comb Chem High Throughput Screen; 2004 Aug; 7(5):453-72. PubMed ID: 15320712
[TBL] [Abstract][Full Text] [Related]
14. Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays.
Xiang J; Yang H; Che C; Zou H; Yang H; Wei Y; Quan J; Zhang H; Yang Z; Lin S
PLoS One; 2009; 4(2):e4361. PubMed ID: 19194508
[TBL] [Abstract][Full Text] [Related]
15. Molecular scaffold-based design and comparison of combinatorial libraries focused on the ATP-binding site of protein kinases.
Stahura FL; Xue L; Godden JW; Bajorath J
J Mol Graph Model; 1999 Feb; 17(1):1-9, 51-2. PubMed ID: 10660905
[TBL] [Abstract][Full Text] [Related]
16. Protein phosphorylation and signal transduction modulation: chemistry perspectives for small-molecule drug discovery.
Sawyer TK; Shakespeare WC; Wang Y; Sundaramoorthi R; Huang WS; Metcalf CA; Thomas M; Lawrence BM; Rozamus L; Noehre J; Zhu X; Narula S; Bohacek RS; Weigele M; Dalgarno DC
Med Chem; 2005 May; 1(3):293-319. PubMed ID: 16787325
[TBL] [Abstract][Full Text] [Related]
17. Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.
Sawyer TK
Expert Opin Investig Drugs; 2004 Jan; 13(1):1-19. PubMed ID: 14680449
[TBL] [Abstract][Full Text] [Related]
18. Structural biology in drug design: selective protein kinase inhibitors.
Scapin G
Drug Discov Today; 2002 Jun; 7(11):601-11. PubMed ID: 12047871
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in designing substrate-competitive protein kinase inhibitors.
Han KC; Kim SY; Yang EG
Curr Pharm Des; 2012; 18(20):2875-82. PubMed ID: 22571656
[TBL] [Abstract][Full Text] [Related]
20. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
